Cargando…
Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174924/ https://www.ncbi.nlm.nih.gov/pubmed/29194590 http://dx.doi.org/10.1002/cpt.954 |
_version_ | 1783361388567068672 |
---|---|
author | Garcia‐Gil, Maria Comas‐Cufí, Marc Blanch, Jordi Martí, Ruth Ponjoan, Anna Alves‐Cabratosa, Lia Petersen, Irene Marrugat, Jaume Elosua, Roberto Grau, María Ramos, Rafel |
author_facet | Garcia‐Gil, Maria Comas‐Cufí, Marc Blanch, Jordi Martí, Ruth Ponjoan, Anna Alves‐Cabratosa, Lia Petersen, Irene Marrugat, Jaume Elosua, Roberto Grau, María Ramos, Rafel |
author_sort | Garcia‐Gil, Maria |
collection | PubMed |
description | The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New users were categorized according to their medical possession ratio (MPR). The main outcome was atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction and ischemic stroke). In adherent patients (MPR 70%), statin treatment decreased ASCVD risk across the range of coronary risk (from 16–30%). The 5‐year number needed to treat (NNT) was 470 and 204 in the risk categories <5% and 5–7.4%, respectively, and 75 and 62 in the 7.5–9.9% category than in the 10–19.9% category, respectively. Statin therapy should remain a priority in patients at high 10‐year CHD risk (10–19.9%). Most patients with intermediate risk could benefit from statin treatment, but the treatment decision should focus on the net benefit, safety, and patient preference, given the higher NNT. |
format | Online Article Text |
id | pubmed-6174924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61749242018-10-10 Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study Garcia‐Gil, Maria Comas‐Cufí, Marc Blanch, Jordi Martí, Ruth Ponjoan, Anna Alves‐Cabratosa, Lia Petersen, Irene Marrugat, Jaume Elosua, Roberto Grau, María Ramos, Rafel Clin Pharmacol Ther Research The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New users were categorized according to their medical possession ratio (MPR). The main outcome was atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction and ischemic stroke). In adherent patients (MPR 70%), statin treatment decreased ASCVD risk across the range of coronary risk (from 16–30%). The 5‐year number needed to treat (NNT) was 470 and 204 in the risk categories <5% and 5–7.4%, respectively, and 75 and 62 in the 7.5–9.9% category than in the 10–19.9% category, respectively. Statin therapy should remain a priority in patients at high 10‐year CHD risk (10–19.9%). Most patients with intermediate risk could benefit from statin treatment, but the treatment decision should focus on the net benefit, safety, and patient preference, given the higher NNT. John Wiley and Sons Inc. 2018-02-02 2018-10 /pmc/articles/PMC6174924/ /pubmed/29194590 http://dx.doi.org/10.1002/cpt.954 Text en © 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Garcia‐Gil, Maria Comas‐Cufí, Marc Blanch, Jordi Martí, Ruth Ponjoan, Anna Alves‐Cabratosa, Lia Petersen, Irene Marrugat, Jaume Elosua, Roberto Grau, María Ramos, Rafel Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title | Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title_full | Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title_fullStr | Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title_full_unstemmed | Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title_short | Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study |
title_sort | effectiveness of statins as primary prevention in people with different cardiovascular risk: a population‐based cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174924/ https://www.ncbi.nlm.nih.gov/pubmed/29194590 http://dx.doi.org/10.1002/cpt.954 |
work_keys_str_mv | AT garciagilmaria effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT comascufimarc effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT blanchjordi effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT martiruth effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT ponjoananna effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT alvescabratosalia effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT petersenirene effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT marrugatjaume effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT elosuaroberto effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT graumaria effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy AT ramosrafel effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy |